Sign In

Login

Password

Forgot Password ? Sign Up

Palmitoyléthanolamide (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Palmitoyléthanolamide" in French language version.

refsWebsite
Global rank French rank
65nih.gov
4th place
12th place
64doi.org
2nd place
3rd place
21semanticscholar.org
11th place
325th place
3harvard.edu
18th place
118th place
2escholarship.org
1,523rd place
2,842nd place
2issn.org
57th place
4th place
2handle.net
102nd place
779th place
2confex.com
6,094th place
6,934th place
2archive.today
14th place
569th place
1qmul.ac.uk
1,735th place
168th place
1acs.org
1,248th place
778th place
1omicsgroup.org
low place
low place
1pathos-journal.com
low place
low place
1yahoo.com
38th place
117th place

acs.org

pubs.acs.org

  • (en) F. A. Kuehl, T. A. Jacob, O. H. Ganley et R. E. Ormond, « THE IDENTIFICATION OF N-(2-HYDROXYETHYL)-PALMITAMIDE AS A NATURALLY OCCURRING ANTI-INFLAMMATORY AGENT », Journal of the American Chemical Society, vol. 79, no 20,‎ , p. 5577–5578 (ISSN 0002-7863 et 1520-5126, DOI 10.1021/ja01577a066, lire en ligne, consulté le )

archive.today

confex.com

iadr.confex.com

doi.org

dx.doi.org

  • « The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations », British Journal of Pharmacology, vol. 174, no 11,‎ , p. 1349–1365 (PMID 27539936, PMCID 5429331, DOI 10.1111/bph.13580).
  • « Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors », British Journal of Pharmacology, vol. 152, no 5,‎ , p. 576–82 (PMID 17704824, PMCID 2190029, DOI 10.1038/sj.bjp.0707423).
  • « The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide », Molecular Pharmacology, vol. 67, no 1,‎ , p. 15–9 (PMID 15465922, DOI 10.1124/mol.104.006353, S2CID 12671741).
  • « Receptors for acylethanolamides-GPR55 and GPR119 », Prostaglandins & Other Lipid Mediators, vol. 89, nos 3–4,‎ , p. 105–11 (PMID 19615459, PMCID 2751869, DOI 10.1016/j.prostaglandins.2009.07.001).
  • « Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease », Immunobiology, vol. 215, no 8,‎ , p. 611–6 (PMID 19833407, DOI 10.1016/j.imbio.2009.09.007).
  • « Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide », British Journal of Pharmacology, vol. 133, no 8,‎ , p. 1263–75 (PMID 11498512, PMCID 1621151, DOI 10.1038/sj.bjp.0704199).
  • « 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors », British Journal of Pharmacology, vol. 155, no 6,‎ , p. 837–46 (PMID 18695637, PMCID 2597234, DOI 10.1038/bjp.2008.324).
  • « Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats », Pharmacological Research, vol. 61, no 4,‎ , p. 321–8 (PMID 19931394, DOI 10.1016/j.phrs.2009.11.005).
  • « Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease », Neuropsychopharmacology, vol. 37, no 7,‎ , p. 1784–92 (PMID 22414817, PMCID 3358748, DOI 10.1038/npp.2012.25).
  • « Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide », European Journal of Pharmacology, vol. 419, nos 2–3,‎ , p. 191–8 (PMID 11426841, DOI 10.1016/S0014-2999(01)00988-8, lire en ligne).
  • (en) « Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-α », Neurotoxicity Research, vol. 19, no 2,‎ , p. 330–40 (PMID 20221904, DOI 10.1007/s12640-010-9166-2, S2CID 8095609).
  • (en) « Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice », Epilepsia, vol. 42, no 3,‎ , p. 321–7 (PMID 11442148, DOI 10.1046/j.1528-1157.2001.41499.x, S2CID 20717112).
  • (en) F. A. Kuehl, T. A. Jacob, O. H. Ganley et R. E. Ormond, « THE IDENTIFICATION OF N-(2-HYDROXYETHYL)-PALMITAMIDE AS A NATURALLY OCCURRING ANTI-INFLAMMATORY AGENT », Journal of the American Chemical Society, vol. 79, no 20,‎ , p. 5577–5578 (ISSN 0002-7863 et 1520-5126, DOI 10.1021/ja01577a066, lire en ligne, consulté le )
  • Jan M Keppel Hesselink, « Professor Rita Levi-Montalcini on Nerve Growth Factor, Mast Cells and Palmitoylethanolamide, an Endogenous Anti-Inflammatory and Analgesic Compound », Journal of Pain & Relief, vol. 02, no 01,‎ (DOI 10.4172/2167-0846.1000114, lire en ligne, consulté le )
  • « Letter: Slow encephalopathies, inflammatory responses, and arachis oil », Lancet, vol. 2, no 7934,‎ , p. 558 (PMID 51386, DOI 10.1016/s0140-6736(75)90939-3, S2CID 54360899).
  • « Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide », Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no 8,‎ , p. 3376–80 (PMID 7724569, PMCID 42169, DOI 10.1073/pnas.92.8.3376, Bibcode 1995PNAS...92.3376F).
  • « Endocannabinoids and related fatty acid derivatives in pain modulation », Chemistry and Physics of Lipids, vol. 121, nos 1–2,‎ , p. 159–72 (PMID 12505698, DOI 10.1016/S0009-3084(02)00152-4).
  • « The palmitoylethanolamide family: a new class of anti-inflammatory agents? », Current Medicinal Chemistry, vol. 9, no 6,‎ , p. 663–74 (PMID 11945130, DOI 10.2174/0929867023370707).
  • « N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation », European Journal of Pharmacology, vol. 300, no 3,‎ , p. 227–36 (PMID 8739213, DOI 10.1016/0014-2999(96)00015-5).
  • « Control of pain initiation by endogenous cannabinoids », Nature, vol. 394, no 6690,‎ , p. 277–81 (PMID 9685157, DOI 10.1038/28393, Bibcode 1998Natur.394..277C, S2CID 4418082, lire en ligne).
  • « Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide », The European Journal of Neuroscience, vol. 28, no 4,‎ , p. 633–41 (PMID 18657182, DOI 10.1111/j.1460-9568.2008.06377.x, hdl 10261/73342, S2CID 11299981).
  • « The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors », Pain, vol. 139, no 3,‎ , p. 541–550 (PMID 18602217, DOI 10.1016/j.pain.2008.06.003, S2CID 7954018).
  • « N-palmitoylethanolamide, an endocannabinoid, exhibits antidepressant effects in the forced swim test and the tail suspension test in mice », Pharmacological Reports, vol. 63, no 3,‎ , p. 834–9 (PMID 21857095, DOI 10.1016/s1734-1140(11)70596-5).
  • « Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial », Investigative Ophthalmology & Visual Science, vol. 52, no 9,‎ , p. 6096–100 (PMID 21705689, DOI 10.1167/iovs.10-7057).
  • « Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury », Brain, Behavior, and Immunity, vol. 25, no 6,‎ , p. 1099–112 (PMID 21354467, DOI 10.1016/j.bbi.2011.02.006, S2CID 11062539).
  • « Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide », Journal of Cellular and Molecular Medicine, vol. 15, no 12,‎ , p. 2664–74 (PMID 21255263, PMCID 4373435, DOI 10.1111/j.1582-4934.2011.01267.x).
  • (en) « Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain », Experimental Neurology, vol. 224, no 1,‎ , p. 48–55 (PMID 20353771, DOI 10.1016/j.expneurol.2010.03.022, S2CID 2069111).
  • (en) « The endocannabinoid system is modulated in response to spinal cord injury in rats », Neurobiology of Disease, vol. 33, no 1,‎ , p. 57–71 (PMID 18930143, DOI 10.1016/j.nbd.2008.09.015, hdl 10261/73343, S2CID 269334).
  • « Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia », Brain Research, vol. 1240,‎ , p. 213–20 (PMID 18823959, DOI 10.1016/j.brainres.2008.09.019, S2CID 26957176).
  • « Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain », Pain, vol. 153, no 1,‎ , p. 33–41 (PMID 21890273, DOI 10.1016/j.pain.2011.08.010, S2CID 24365083).
  • « Smoked cannabis for chronic neuropathic pain: a randomized controlled trial », CMAJ, vol. 182, no 14,‎ , E694-701 (PMID 20805210, PMCID 2950205, DOI 10.1503/cmaj.091414).
  • « The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons », Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no 9,‎ , p. 3984–9 (PMID 8633002, PMCID 39472, DOI 10.1073/pnas.93.9.3984, Bibcode 1996PNAS...93.3984S).
  • « Palmitoylethanolamide stimulation induces allopregnanolone synthesis in C6 Cells and primary astrocytes: involvement of peroxisome-proliferator activated receptor-α », Journal of Neuroendocrinology, vol. 23, no 7,‎ , p. 591–600 (PMID 21554431, DOI 10.1111/j.1365-2826.2011.02152.x, S2CID 25234676).
  • « Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats », Molecular Pain, vol. 7,‎ , p. 1744-8069-7-3 (PMID 21219627, PMCID 3034677, DOI 10.1186/1744-8069-7-3).
  • « Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells », Veterinary Immunology and Immunopathology, vol. 133, no 1,‎ , p. 9–15 (PMID 19625089, DOI 10.1016/j.vetimm.2009.06.011).
  • « Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in rats », Journal of Cellular and Molecular Medicine, vol. 13, no 6,‎ , p. 1086–95 (PMID 18429935, PMCID 4496105, DOI 10.1111/j.1582-4934.2008.00353.x).
  • « Palmitoylethanolamide reduces early renal dysfunction and injury caused by experimental ischemia and reperfusion in mice », Shock, vol. 38, no 4,‎ , p. 356–66 (PMID 22772472, DOI 10.1097/SHK.0b013e318267bbb9, S2CID 35074720).
  • « Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies », Neuropharmacology, vol. 48, no 8,‎ , p. 1154–63 (PMID 15910891, DOI 10.1016/j.neuropharm.2005.01.001, S2CID 14828175).
  • « The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain », Pain, vol. 76, nos 1–2,‎ , p. 189–99 (PMID 9696473, DOI 10.1016/S0304-3959(98)00041-4, S2CID 6250848).
  • « Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder », Anesthesiology, vol. 94, no 3,‎ , p. 507–13; discussion 6A (PMID 11374613, DOI 10.1097/00000542-200103000-00023, S2CID 1282800).
  • « Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide », Pain Medicine, vol. 11, no 5,‎ , p. 781–4 (PMID 20345619, DOI 10.1111/j.1526-4637.2010.00823.x).
  • (en) « Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations », European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 150, no 1,‎ , p. 76–9 (PMID 20176435, DOI 10.1016/j.ejogrb.2010.01.008).
  • « A proposed autacoid mechanism controlling mastocyte behaviour », Agents and Actions, vol. 39,‎ , C145–C147 (PMID 7505999, DOI 10.1007/BF01972748, S2CID 20577242).
  • « Central nervous system mast cells in peripheral inflammatory nociception », Molecular Pain, vol. 7,‎ , p. 1744-8069-7-42 (PMID 21639869, PMCID 3123586, DOI 10.1186/1744-8069-7-42).
  • « Palmitoylethanolamide relieves pain and preserves pancreatic islet cells in a murine model of diabetes », CNS & Neurological Disorders Drug Targets, vol. 14, no 4,‎ , p. 452–62 (PMID 25921749, DOI 10.2174/1871527314666150429111537).
  • « Spinal astrocytes as therapeutic targets for pathological pain », Journal of Pharmacological Sciences, vol. 114, no 4,‎ , p. 347–53 (PMID 21081837, DOI 10.1254/jphs.10r04cp).
  • « Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain », Molecular Pain, vol. 5,‎ , p. 1744-8069-5-35 (PMID 19570201, PMCID 2719614, DOI 10.1186/1744-8069-5-35).
  • « Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study) », Journal of the European Academy of Dermatology and Venereology, vol. 22, no 1,‎ , p. 73–82 (PMID 18181976, DOI 10.1111/j.1468-3083.2007.02351.x, S2CID 22183787).
  • « Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia », Journal der Deutschen Dermatologischen Gesellschaft, vol. 8, no 2,‎ , p. 88–91 (PMID 19744255, DOI 10.1111/j.1610-0387.2009.07213.x, S2CID 36048790).
  • « Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs », Veterinary Journal, vol. 191, no 3,‎ , p. 377–82 (PMID 21601500, DOI 10.1016/j.tvjl.2011.04.002).
  • « The Basal Pharmacology of Palmitoylethanolamide », International Journal of Molecular Sciences, vol. 21, no 21,‎ , p. 7942 (PMID 33114698, PMCID 7662788, DOI 10.3390/ijms21217942).
  • (en) « Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators », The Journal of Allergy and Clinical Immunology, vol. 125, no 1,‎ , p. 160–9.e1–5 (PMID 19818482, PMCID 2859962, DOI 10.1016/j.jaci.2009.06.049).
  • « Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: results of an open-label six-month follow-up », Journal of Medicinal Food, vol. 17, no 9,‎ , p. 949–54 (PMID 24827384, DOI 10.1089/jmf.2013.0165).
  • « Palmitoylethanolamide effects on intraocular pressure after Nd:YAG laser iridotomy: an experimental clinical study », Journal of Ocular Pharmacology and Therapeutics, vol. 27, no 6,‎ , p. 629–35 (PMID 21830944, DOI 10.1089/jop.2010.0191).
  • « Mechanisms of exercise-induced hypoalgesia », The Journal of Pain, vol. 15, no 12,‎ , p. 1294–1304 (PMID 25261342, PMCID 4302052, DOI 10.1016/j.jpain.2014.09.006).
  • « N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities », Biochimie, vol. 92, no 6,‎ , p. 724–7 (PMID 20096327, DOI 10.1016/j.biochi.2010.01.006).
  • « Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells », Journal of Pain Research, vol. 6,‎ , p. 239–45 (PMID 23658493, PMCID 3643547, DOI 10.2147/JPR.S42417).
  • « Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy », CNS & Neurological Disorders Drug Targets, vol. 10, no 8,‎ , p. 916–20 (PMID 22229320, DOI 10.2174/187152711799219307).
  • « Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold », International Journal of Inflammation, vol. 2013,‎ , p. 151028 (PMID 24066256, PMCID 3771453, DOI 10.1155/2013/151028).
  • « Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity », British Journal of Anaesthesia, vol. 123, no 2,‎ , e249–e253 (PMID 30929760, PMCID 6676009, DOI 10.1016/j.bja.2019.02.019).
  • « Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19 », Medical Hypotheses, vol. 143,‎ , p. 109856 (PMID 32460208, PMCID 7236677, DOI 10.1016/j.mehy.2020.109856).
  • « The N-acylethanolamine-hydrolyzing acid amidase (NAAA) », Chemistry & Biodiversity, vol. 4, no 8,‎ , p. 1914–25 (PMID 17712833, DOI 10.1002/cbdv.200790159, S2CID 32163665).
  • « Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy », British Journal of Clinical Pharmacology, vol. 82, no 4,‎ , p. 932–42 (PMID 27220803, PMCID 5094513, DOI 10.1111/bcp.13020).
  • « Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis », Pain Physician, vol. 19, no 2,‎ , p. 11–24 (PMID 26815246, DOI 10.36076/ppj/2016.19.11).

escholarship.org

handle.net

hdl.handle.net

harvard.edu

ui.adsabs.harvard.edu

issn.org

portal.issn.org

  • (en) F. A. Kuehl, T. A. Jacob, O. H. Ganley et R. E. Ormond, « THE IDENTIFICATION OF N-(2-HYDROXYETHYL)-PALMITAMIDE AS A NATURALLY OCCURRING ANTI-INFLAMMATORY AGENT », Journal of the American Chemical Society, vol. 79, no 20,‎ , p. 5577–5578 (ISSN 0002-7863 et 1520-5126, DOI 10.1021/ja01577a066, lire en ligne, consulté le )
  • (it + en) Desio, P., « Associazione tra pregabalin e palmitoiletanolamide (PEA) per il trattamento del dolore neuropatico », Pathos, Milan, Italie, Società italiana dei clinici del dolore/PubliEditing, vol. 17, no 4,‎ , p. 9–14 (ISSN 2385-0744, lire en ligne, consulté le ).

nih.gov

ncbi.nlm.nih.gov

  • « The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations », British Journal of Pharmacology, vol. 174, no 11,‎ , p. 1349–1365 (PMID 27539936, PMCID 5429331, DOI 10.1111/bph.13580).
  • « Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors », British Journal of Pharmacology, vol. 152, no 5,‎ , p. 576–82 (PMID 17704824, PMCID 2190029, DOI 10.1038/sj.bjp.0707423).
  • « The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide », Molecular Pharmacology, vol. 67, no 1,‎ , p. 15–9 (PMID 15465922, DOI 10.1124/mol.104.006353, S2CID 12671741).
  • « Receptors for acylethanolamides-GPR55 and GPR119 », Prostaglandins & Other Lipid Mediators, vol. 89, nos 3–4,‎ , p. 105–11 (PMID 19615459, PMCID 2751869, DOI 10.1016/j.prostaglandins.2009.07.001).
  • « Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease », Immunobiology, vol. 215, no 8,‎ , p. 611–6 (PMID 19833407, DOI 10.1016/j.imbio.2009.09.007).
  • « Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide », British Journal of Pharmacology, vol. 133, no 8,‎ , p. 1263–75 (PMID 11498512, PMCID 1621151, DOI 10.1038/sj.bjp.0704199).
  • « 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors », British Journal of Pharmacology, vol. 155, no 6,‎ , p. 837–46 (PMID 18695637, PMCID 2597234, DOI 10.1038/bjp.2008.324).
  • « Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats », Pharmacological Research, vol. 61, no 4,‎ , p. 321–8 (PMID 19931394, DOI 10.1016/j.phrs.2009.11.005).
  • « Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease », Neuropsychopharmacology, vol. 37, no 7,‎ , p. 1784–92 (PMID 22414817, PMCID 3358748, DOI 10.1038/npp.2012.25).
  • « Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide », European Journal of Pharmacology, vol. 419, nos 2–3,‎ , p. 191–8 (PMID 11426841, DOI 10.1016/S0014-2999(01)00988-8, lire en ligne).
  • (en) « Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-α », Neurotoxicity Research, vol. 19, no 2,‎ , p. 330–40 (PMID 20221904, DOI 10.1007/s12640-010-9166-2, S2CID 8095609).
  • (en) « Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice », Epilepsia, vol. 42, no 3,‎ , p. 321–7 (PMID 11442148, DOI 10.1046/j.1528-1157.2001.41499.x, S2CID 20717112).
  • « Letter: Slow encephalopathies, inflammatory responses, and arachis oil », Lancet, vol. 2, no 7934,‎ , p. 558 (PMID 51386, DOI 10.1016/s0140-6736(75)90939-3, S2CID 54360899).
  • « Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide », Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no 8,‎ , p. 3376–80 (PMID 7724569, PMCID 42169, DOI 10.1073/pnas.92.8.3376, Bibcode 1995PNAS...92.3376F).
  • « Endocannabinoids and related fatty acid derivatives in pain modulation », Chemistry and Physics of Lipids, vol. 121, nos 1–2,‎ , p. 159–72 (PMID 12505698, DOI 10.1016/S0009-3084(02)00152-4).
  • « The palmitoylethanolamide family: a new class of anti-inflammatory agents? », Current Medicinal Chemistry, vol. 9, no 6,‎ , p. 663–74 (PMID 11945130, DOI 10.2174/0929867023370707).
  • « N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation », European Journal of Pharmacology, vol. 300, no 3,‎ , p. 227–36 (PMID 8739213, DOI 10.1016/0014-2999(96)00015-5).
  • « Control of pain initiation by endogenous cannabinoids », Nature, vol. 394, no 6690,‎ , p. 277–81 (PMID 9685157, DOI 10.1038/28393, Bibcode 1998Natur.394..277C, S2CID 4418082, lire en ligne).
  • « Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide », The European Journal of Neuroscience, vol. 28, no 4,‎ , p. 633–41 (PMID 18657182, DOI 10.1111/j.1460-9568.2008.06377.x, hdl 10261/73342, S2CID 11299981).
  • « The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors », Pain, vol. 139, no 3,‎ , p. 541–550 (PMID 18602217, DOI 10.1016/j.pain.2008.06.003, S2CID 7954018).
  • « N-palmitoylethanolamide, an endocannabinoid, exhibits antidepressant effects in the forced swim test and the tail suspension test in mice », Pharmacological Reports, vol. 63, no 3,‎ , p. 834–9 (PMID 21857095, DOI 10.1016/s1734-1140(11)70596-5).
  • « Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial », Investigative Ophthalmology & Visual Science, vol. 52, no 9,‎ , p. 6096–100 (PMID 21705689, DOI 10.1167/iovs.10-7057).
  • « Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury », Brain, Behavior, and Immunity, vol. 25, no 6,‎ , p. 1099–112 (PMID 21354467, DOI 10.1016/j.bbi.2011.02.006, S2CID 11062539).
  • « Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide », Journal of Cellular and Molecular Medicine, vol. 15, no 12,‎ , p. 2664–74 (PMID 21255263, PMCID 4373435, DOI 10.1111/j.1582-4934.2011.01267.x).
  • (en) « Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain », Experimental Neurology, vol. 224, no 1,‎ , p. 48–55 (PMID 20353771, DOI 10.1016/j.expneurol.2010.03.022, S2CID 2069111).
  • (en) « The endocannabinoid system is modulated in response to spinal cord injury in rats », Neurobiology of Disease, vol. 33, no 1,‎ , p. 57–71 (PMID 18930143, DOI 10.1016/j.nbd.2008.09.015, hdl 10261/73343, S2CID 269334).
  • « Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia », Brain Research, vol. 1240,‎ , p. 213–20 (PMID 18823959, DOI 10.1016/j.brainres.2008.09.019, S2CID 26957176).
  • « Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain », Pain, vol. 153, no 1,‎ , p. 33–41 (PMID 21890273, DOI 10.1016/j.pain.2011.08.010, S2CID 24365083).
  • « Smoked cannabis for chronic neuropathic pain: a randomized controlled trial », CMAJ, vol. 182, no 14,‎ , E694-701 (PMID 20805210, PMCID 2950205, DOI 10.1503/cmaj.091414).
  • « The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons », Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no 9,‎ , p. 3984–9 (PMID 8633002, PMCID 39472, DOI 10.1073/pnas.93.9.3984, Bibcode 1996PNAS...93.3984S).
  • « Palmitoylethanolamide stimulation induces allopregnanolone synthesis in C6 Cells and primary astrocytes: involvement of peroxisome-proliferator activated receptor-α », Journal of Neuroendocrinology, vol. 23, no 7,‎ , p. 591–600 (PMID 21554431, DOI 10.1111/j.1365-2826.2011.02152.x, S2CID 25234676).
  • « Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats », Molecular Pain, vol. 7,‎ , p. 1744-8069-7-3 (PMID 21219627, PMCID 3034677, DOI 10.1186/1744-8069-7-3).
  • « Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells », Veterinary Immunology and Immunopathology, vol. 133, no 1,‎ , p. 9–15 (PMID 19625089, DOI 10.1016/j.vetimm.2009.06.011).
  • « Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in rats », Journal of Cellular and Molecular Medicine, vol. 13, no 6,‎ , p. 1086–95 (PMID 18429935, PMCID 4496105, DOI 10.1111/j.1582-4934.2008.00353.x).
  • « Palmitoylethanolamide reduces early renal dysfunction and injury caused by experimental ischemia and reperfusion in mice », Shock, vol. 38, no 4,‎ , p. 356–66 (PMID 22772472, DOI 10.1097/SHK.0b013e318267bbb9, S2CID 35074720).
  • « Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies », Neuropharmacology, vol. 48, no 8,‎ , p. 1154–63 (PMID 15910891, DOI 10.1016/j.neuropharm.2005.01.001, S2CID 14828175).
  • « The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain », Pain, vol. 76, nos 1–2,‎ , p. 189–99 (PMID 9696473, DOI 10.1016/S0304-3959(98)00041-4, S2CID 6250848).
  • « Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder », Anesthesiology, vol. 94, no 3,‎ , p. 507–13; discussion 6A (PMID 11374613, DOI 10.1097/00000542-200103000-00023, S2CID 1282800).
  • « Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide », Pain Medicine, vol. 11, no 5,‎ , p. 781–4 (PMID 20345619, DOI 10.1111/j.1526-4637.2010.00823.x).
  • (en) « Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations », European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 150, no 1,‎ , p. 76–9 (PMID 20176435, DOI 10.1016/j.ejogrb.2010.01.008).
  • « A proposed autacoid mechanism controlling mastocyte behaviour », Agents and Actions, vol. 39,‎ , C145–C147 (PMID 7505999, DOI 10.1007/BF01972748, S2CID 20577242).
  • « Central nervous system mast cells in peripheral inflammatory nociception », Molecular Pain, vol. 7,‎ , p. 1744-8069-7-42 (PMID 21639869, PMCID 3123586, DOI 10.1186/1744-8069-7-42).
  • « Palmitoylethanolamide relieves pain and preserves pancreatic islet cells in a murine model of diabetes », CNS & Neurological Disorders Drug Targets, vol. 14, no 4,‎ , p. 452–62 (PMID 25921749, DOI 10.2174/1871527314666150429111537).
  • « Spinal astrocytes as therapeutic targets for pathological pain », Journal of Pharmacological Sciences, vol. 114, no 4,‎ , p. 347–53 (PMID 21081837, DOI 10.1254/jphs.10r04cp).
  • « Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain », Molecular Pain, vol. 5,‎ , p. 1744-8069-5-35 (PMID 19570201, PMCID 2719614, DOI 10.1186/1744-8069-5-35).
  • « Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study) », Journal of the European Academy of Dermatology and Venereology, vol. 22, no 1,‎ , p. 73–82 (PMID 18181976, DOI 10.1111/j.1468-3083.2007.02351.x, S2CID 22183787).
  • « Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist », Minerva Medica, vol. 102, no 2,‎ , p. 141–7 (PMID 21483401).
  • « Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia », Journal der Deutschen Dermatologischen Gesellschaft, vol. 8, no 2,‎ , p. 88–91 (PMID 19744255, DOI 10.1111/j.1610-0387.2009.07213.x, S2CID 36048790).
  • « Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs », Veterinary Journal, vol. 191, no 3,‎ , p. 377–82 (PMID 21601500, DOI 10.1016/j.tvjl.2011.04.002).
  • « The Basal Pharmacology of Palmitoylethanolamide », International Journal of Molecular Sciences, vol. 21, no 21,‎ , p. 7942 (PMID 33114698, PMCID 7662788, DOI 10.3390/ijms21217942).
  • « Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis », Pain Physician, vol. 20, no 5,‎ , p. 353–362 (PMID 28727699, lire en ligne).
  • (en) « Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators », The Journal of Allergy and Clinical Immunology, vol. 125, no 1,‎ , p. 160–9.e1–5 (PMID 19818482, PMCID 2859962, DOI 10.1016/j.jaci.2009.06.049).
  • « Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: results of an open-label six-month follow-up », Journal of Medicinal Food, vol. 17, no 9,‎ , p. 949–54 (PMID 24827384, DOI 10.1089/jmf.2013.0165).
  • « Palmitoylethanolamide effects on intraocular pressure after Nd:YAG laser iridotomy: an experimental clinical study », Journal of Ocular Pharmacology and Therapeutics, vol. 27, no 6,‎ , p. 629–35 (PMID 21830944, DOI 10.1089/jop.2010.0191).
  • « Mechanisms of exercise-induced hypoalgesia », The Journal of Pain, vol. 15, no 12,‎ , p. 1294–1304 (PMID 25261342, PMCID 4302052, DOI 10.1016/j.jpain.2014.09.006).
  • « N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities », Biochimie, vol. 92, no 6,‎ , p. 724–7 (PMID 20096327, DOI 10.1016/j.biochi.2010.01.006).
  • « Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells », Journal of Pain Research, vol. 6,‎ , p. 239–45 (PMID 23658493, PMCID 3643547, DOI 10.2147/JPR.S42417).
  • « Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy », CNS & Neurological Disorders Drug Targets, vol. 10, no 8,‎ , p. 916–20 (PMID 22229320, DOI 10.2174/187152711799219307).
  • « Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold », International Journal of Inflammation, vol. 2013,‎ , p. 151028 (PMID 24066256, PMCID 3771453, DOI 10.1155/2013/151028).
  • « Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity », British Journal of Anaesthesia, vol. 123, no 2,‎ , e249–e253 (PMID 30929760, PMCID 6676009, DOI 10.1016/j.bja.2019.02.019).
  • « Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19 », Medical Hypotheses, vol. 143,‎ , p. 109856 (PMID 32460208, PMCID 7236677, DOI 10.1016/j.mehy.2020.109856).
  • « The N-acylethanolamine-hydrolyzing acid amidase (NAAA) », Chemistry & Biodiversity, vol. 4, no 8,‎ , p. 1914–25 (PMID 17712833, DOI 10.1002/cbdv.200790159, S2CID 32163665).
  • « Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy », British Journal of Clinical Pharmacology, vol. 82, no 4,‎ , p. 932–42 (PMID 27220803, PMCID 5094513, DOI 10.1111/bcp.13020).
  • « Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis », Pain Physician, vol. 19, no 2,‎ , p. 11–24 (PMID 26815246, DOI 10.36076/ppj/2016.19.11).

pubmed.ncbi.nlm.nih.gov

  • « Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis », Pain Physician, vol. 20, no 5,‎ , p. 353–362 (PMID 28727699, lire en ligne).

omicsgroup.org

  • Jan M Keppel Hesselink, « Professor Rita Levi-Montalcini on Nerve Growth Factor, Mast Cells and Palmitoylethanolamide, an Endogenous Anti-Inflammatory and Analgesic Compound », Journal of Pain & Relief, vol. 02, no 01,‎ (DOI 10.4172/2167-0846.1000114, lire en ligne, consulté le )

pathos-journal.com

  • (it + en) Desio, P., « Associazione tra pregabalin e palmitoiletanolamide (PEA) per il trattamento del dolore neuropatico », Pathos, Milan, Italie, Società italiana dei clinici del dolore/PubliEditing, vol. 17, no 4,‎ , p. 9–14 (ISSN 2385-0744, lire en ligne, consulté le ).

qmul.ac.uk

chem.qmul.ac.uk

semanticscholar.org

api.semanticscholar.org

yahoo.com

finance.yahoo.com

  • (en) Steven Ralston, « HUGE.CN: FSD Pharma is conducting Phase 1 clinical trial of FSD-201 for inflammation and has FDA approval for a Phase 2a clinical trial design for the treatment of COVID-19 patients », Yahoo!,‎ (lire en ligne, consulté le ).